Revealing the lurking risk of relapes

In preparation for the launch of ADCETRIS—one of the first commercialized antibody drug conjugates and the first and only ADC in hodgkin lymphoma—GENICOS identified a high risk of post-transplant relapse—a fact that needed to be highlighted for prescribers. This subtle, yet stunning campaign image earned high awareness scores and numerous creative awards.